Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cerebral Amyloid Angiopathy: early-phase trial registry
2 of 3 indexed Cerebral Amyloid Angiopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Cerebral Amyloid Angiopathy: 3 US clinical trials tracked, 2 recruiting.
Cerebral Amyloid Angiopathy is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Amydis, running 1 of these trials.
Enrollment posture brief
Registry condition cerebral-amyloid-angiopathy
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Cerebral Amyloid Angiopathy lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cerebral Amyloid Angiopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cerebral Amyloid Angiopathy is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals
NCT06393712
A Study of AMDX-2011P in Participants With CAA
Amydis
NCT05709314
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Pfizer
NCT01821118
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Cerebral Amyloid Angiopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cerebral Amyloid Angiopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cerebral Amyloid Angiopathy page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Cerebral Amyloid Angiopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amydis sponsors the most Cerebral Amyloid Angiopathy trials on record, review their full trial history before evaluating a specific study. See Amydis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cerebral Amyloid Angiopathy condition card totals 3 registered trials; most-linked intervention Ponezumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.